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Abstract
BACKGROUND—Recent experimental evidence suggests that DNA damage and cell cycle
regulatory proteins are involved in kidney injury and apoptosis. The checkpoint 2 gene (CHEK2)
is an important transducer in DNA damage signaling pathways in response to injury, and
therefore, CHEK2 variants may affect susceptibility to kidney disease.
METHODS—We used tag-single-nucleotide polymorphisms (tag-SNPs) to evaluate the
association of the CHEK2 with kidney function (estimated glomerular filtration rate, eGFR) in
1,549 African-American and 1,423 white Hypertension Genetic Epidemiology Network
(HyperGEN) participants. We performed replication analyses in the Genetic Epidemiology
Network of Arteriopathy (GENOA) participants (1,746 African Americans and 1,418 whites),
GenNet participants (706 whites), and Atherosclerosis Risk in Communities (ARIC) study
participants (3,783 African Americans and 10,936 whites). All analyses were race-stratified and
used additive genetic models with adjustments for covariates and for family structure, if needed.
RESULTS—One tag-SNP, rs5762764, was associated with eGFR in HyperGEN P = (0.003) and
GENOA white participants (P = 0.009), and it was significantly associated with eGFR in meta-
analyses (P = 0.002). The associations were independent of type 2 diabetes.
CONCLUSIONS—These results suggest that CHEK2 variants may influence eGFR in the
context of hypertension.
Chronic kidney disease (CKD) is an emerging public health problem with an estimated
prevalence of 9.6% (or 19.2 million) of the adult US population.1,2 CKD is a strong risk
factor for cardiovascular disease,3 is associated with increased morbidity and mortality,4,5
increased health-care resource use,6 and a decreased quality of life.7 The economic burden
associated with the treatment of kidney failure is substantial, accounting for 6.8% of the
health-care expenditures in 2004.8,9
Familial aggregation of CKD has been documented.10,11 A high heritability of renal
function has been noted in twin studies (0.78 ± 0.03 for glomerular filtration rate—GFR).12
A genetic component for kidney traits has also been identified in studies of type 1 and type 2
diabetic study participants,13–17 in hypertensive study participants18–21 and in the general
population.22,23 Although several monogenic kidney diseases have been identified, little
progress has been achieved in identifying susceptibility genes for CKD in individuals with
diabetes and/or hypertension,24,25 the two most common conditions associated with kidney
failure.8,9 Genetic heterogeneity may introduce analytical challenges for the identification
of genetic variants influencing kidney function, and may account for the lack of genome-
wide significant findings in a recent genome-wide association study of kidney-related
phenotypes.26 Therefore, candidate gene approaches interrogating genes from newly
discovered pathways of kidney injury may constitute a complementary approach to large-
scale genome-wide gene finding studies.
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Genetic and environmental factors (for example, endogenous and exogenous toxins) likely
contribute to CKD susceptibility. Programmed cell death or apoptosis of intrinsic kidney
cells in response to injury has been described in experimental animal models and in humans.
27 Recent research suggests a role for reactive oxygen species and DNA damage in the
membrane attack complex C5b-9 injury (passive Heymann nephritis),28 in puromycin
nephrosis,29 and in cisplatin nephrotoxicity.30 DNA damage leads to activation of the
checkpoint pathways, which mediate cell cycle arrest and apoptosis.31,32 Therefore, genes
in the DNA repair and cell cycle checkpoint pathways are excellent candidates for
evaluation of association with kidney function.
The checkpoint 2 gene (CHEK2) is an important transducer in DNA damage signaling
pathways in response to injury. We have previously identified the CHEK2 gene under a
linkage peak for type 2 diabetes among 3,383 Hypertension Genetic Epidemiology Network
(HyperGEN) participants.33 The 22q12 chromosome region, where CHEK2 is located, has
been identified in linkage and in admixture studies of kidney phenotypes.14,18,34,35 In this
study, we tested the hypothesis that CHEK2 contains one or more polymorphic variants
(single-nucleotide polymorphisms (SNPs)) that are associated with kidney function in
participants of the HyperGEN study. We attempted to replicate our association in three
additional populations, the Genetic Epidemiology Network of Arteriopathy (GENOA) study,
the GenNet study, and the Atherosclerosis Risk in Communities (ARIC) study.
Methods
Populations, phenotypes, and covariates
Family Blood Pressure Program—The Family Blood Pressure Program (FBPP),
composed of four independent networks without overlap in participants (HyperGEN,
GENOA, GenNet, and SAPPHIRe), was established to investigate the genetic determinants
of high blood pressure (BP) in multiple ethnic groups.36 Families were ascertained based on
higher than normal BP or diagnosed hypertension. This study includes only genotyped
participants of the FBPP HyperGEN, GENOA, and GenNet studies.
HyperGEN recruited African-American and non-Hispanic white hypertensive siblings and
their offspring and/or parents. A family was eligible for participation if at least two siblings
had BP measurements ≥140/90 mm Hg or used antihypertensive medications, with the age
of diagnosis of <60 years. GENOA recruited African-American, Mexican-American, and
non-Hispanic white sibships containing a minimum of two individuals diagnosed with
hypertension. GenNet recruited African-American and non-Hispanic white individuals with
BP in the upper 20–25% of the age- and gender-specific BP distribution, and all available
first degree relatives.
All networks measured a standard set of 95 core phenotypes.36 Clinical, lifestyle
information, and medications were obtained via an interview. Body mass index was
calculated using weight (kg)/height (m2), obtained during a clinic visit. Tobacco exposure
was quantified using questionnaires. Resting BP measurements were obtained using
automated Dinamap devices (model 1846 SX/P; GE Medical Systems, Tampa, FL) and
hypertension was defined by a BP of at least 140/90 mm Hg or use of antihypertensive
medications. Individuals with a fasting plasma glucose of at least 7.0 mmol/l (126 mg/dl) or
using medications to treat diabetes were defined as having type 2 diabetes.37 Individuals
with age of onset of diabetes <30 years old were considered type 1 diabetics and therefore
excluded.
In HyperGEN, serum creatinine was measured by a thin-film adaptation of the
amidohydrolase enzymatic method using the Vitros analyzer (Johnson & Johnson Clinical
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Diagnostics, Raritan, NJ).38 GENOA measured serum creatinine using a picric acid
colorimetric assay (Monarch Chemistry System, Lexington, MA), and calibrated serum
creatinine to the Cleveland Clinic assay by subtracting 0.17 mg/dl from measured values
(S.T. Turner, unpublished data). GenNet measured serum creatinine only in white
individuals (using a modified Jaffe reaction). GFR was estimated using the Modification of
Diet in Renal Disease equation.39 CKD was defined as an estimated GFR (eGFR) <60 ml/
min/1.73 m2.
ARIC
ARIC is a biracial prospective population study of subclinical and clinical atherosclerosis of
15,792 unrelated individuals, aged 45–64 years old at recruitment (1987–1989).40 Study
participants were selected as a probability sample from four US communities and were
examined at baseline (visit 1) and at every 3 years through January 1999.
Resting BP was recorded in seated individuals using a random-zero sphygmomanometer,
and hypertension was defined using the same criteria as for the FBPP. Type 2 diabetes was
defined by a fasting plasma glucose of at least 7.0 mmol/l, nonfasting glucose levels of at
least 11.1 mmol/l, current use of medications prescribed to treat diabetes (e.g., insulin or
sulfonylurea), or a positive response to the question “Has a doctor ever told you that you had
diabetes ?”. Smoking was assessed using a questionnaire and anthropometric measures were
obtained during clinic visits. Serum creatinine was measured using a modified kinetic Jaffe
reaction, and calibrated using regression to the Cleveland Clinic laboratory by subtraction of
0.24 mg/dl.41 eGFR was estimated using serum creatinine from the visit 1 and the
Modification of Diet in Renal Disease equation. eGFR values >200 were set to 200 ml/min/
1.73 m2.
All participants of the FPPP and ARIC studies provided informed consent. The study was
conducted in accordance with the principles of the Declaration of Helsinki.
Selection and genotyping of SNPs
DNA extraction and storage procedures in the FBPP and ARIC studies are described
elsewhere.42,43 CHEK2 SNP selection is described in detail in the Supplementary Data
online. Briefly, SNPs were chosen using the HapMap phase 1 CEU sample and a pairwise
analysis of correlation (r2 = 0.65). The r2 statistics measures the linkage disequilibrium
between two markers or how well an allele predicts the allele at the other locus.44
Therefore, it can be used to select a subset of SNPs within a gene (tag-SNPs) for
genotyping.45 A selected number of SNPs was genotyped in the replication populations, as
part of an ongoing study of diabetes susceptibility (data not shown).
An additional SNP, rs2346397, located 200 kb from CHEK2, was also available for
analyses. Genotyping for all samples was performed using Taqman SNP Genotyping Assays
(Applied Biosystems, Foster City, CA). The assay call rates were 99% for HyperGEN and
GenNet samples, and >95% for GENOA and ARIC samples. We tested for Hardy–
Weinberg equilibrium in race-stratified samples by study populations and none of the SNPs
had significant deviation of Hardy–Weinberg equilibrium (Supplementary Table S1 online).
Statistical analysis
We tested the association between CHEK2 SNPs and eGFR using general linear mixed
models in the FPPP and linear regression models in the ARIC study. eGFR had a normal
distribution and therefore was not transformed for analyses. We estimated genotypic means
and 95% confidence intervals using empirical covariance matrix structures to account for the
correlation within the data due to family relatedness (SAS version 9.1, SAS Institute, Cary,
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NC). All analyses were linear models, using additive genetic models (1-degree of freedom
test) and adjusting for age, age2, sex, age-by-sex interactions, and study center, within each
race-stratified population sample (model 1). We further adjusted for systolic BP,
hypertension treatment (or use of angiotensin-enzyme converting inhibitor or angiotensin 2
receptor blocker), type 2 diabetes, body mass index, and smoking exposure (model 2). We
also explored models excluding individuals with type 2 diabetes (model 3, Supplementary
Data online). In the ARIC study, we study the interaction of hypertension and type 2
diabetes on the association of SNPs and eGFR using interaction terms (α = 0.10) and
stratified analyses. For family studies, we tested the association using the quantitative trait
disequilibrium test implemented in SOLAR, which accounts for linkage and the family
structure of these data as well as population structure.46 Because P values were similar in
analyses using the quantitative trait disequilibrium test and mixed linear models, but mixed
models provided estimates of the effect, we only report results for the mixed models.
Haplotypes were inferred using the Family Base Association Testing software47,48 in
family studies, and HAPSTAT49 in studies of unrelated individuals. We performed fixed
effects meta-analysis by combining estimated regression coefficients and standard errors
across samples (STATA 10), weighting by the inverse variance of each study.50 We also
tested for the presence of between-study heterogeneity.51
RESULTS
In our primary sample, we studied 1,423 white and 1,549 African-American HyperGEN
participants, mostly hypertensive individuals (Table 1). The mean eGFR were 76.9 ± 16.5
and 92.4 ± 22.3 ml/min/1.73 m2, for white and African-American individuals, respectively.
Minor allele frequencies varied by race/ethnicity, with a large difference between white and
African-American participants observed for the rs5762764 SNP (Supplementary Table S1
online). Haplotypes with the minor allele for rs5762764 (G allele) were uncommon in
African-American individuals (Supplementary Table S2 online).
rs5762764 was significantly associated with eGFR in HyperGEN white individuals (P=
0.003, model 1) (Table 2). The presence of one or two copies of minor allele was associated
with higher eGFR among white individuals (Table 2). The association was still significant
when individuals with type 2 diabetes were excluded (P = 0.01, Supplementary Data
online). The SNPs were not associated with eGFR in HyperGEN African-American
individuals (Table 2).
For replication of our findings, we performed analyses of 1,418 white and 1,746 African-
American GENOA participants, and 706 GenNet white individuals with available data on
eGFR. Minor allele frequencies by race were similar to HyperGEN samples (Supplementary
Table S1 online). Participants of the GENOA and GenNet were often hypertensive, and
those in GenNet were younger, on average, than those in HyperGEN or GENOA (Table 1).
We observed a significant association of rs5762764 with eGFR among GENOA whites
(Table 3). The minor allele for rs5762764 was associated with higher eGFR among these
individuals (P = 0.009, model 1). The association was still significant in analyses excluding
diabetic individuals (P = 0.006, Supplementary Data online). Although eGFR was higher in
GenNet white participants with two copies of the minor allele for rs5762764, the association
was not significant (Table 3). None of the SNPs was significantly associated with eGFR
among GENOA African Americans.
We also performed analysis of 10,936 white and 3,783 African-American individuals from
the ARIC study. The mean eGFRs and other characteristics of these samples are displayed in
Table 1. rs5762764 was not associated with eGFR in white or African-American ARIC
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participants (Table 3). However, because our results were more consistent among white
individuals from samples ascertained for hypertension, we examined interactions of
hypertension in the association between SNP-eGFR in the ARIC study. rs5762764 was
significantly associated with eGFR among white individuals (P = 0.04, model 1) when
accounting for hypertension interaction (P = 0.08 for interaction). The hypertension
subsample displayed a genotype effect that was consistent with the other hypertension
subsamples from HyperGEN, GENOA, and GenNet (Supplementary Data online).
In meta-analysis, rs5762764 was significant associated with eGFR (P = 0.002), with a
combined estimated regression coefficient of 0.60 (Figure 1).
DISCUSSION
Recent experimental evidence suggests that DNA damage and cell cycle regulatory proteins
are involved in kidney injury and apoptosis.52 The DNA repair pathway involves multiple
mediators that in response to injury lead to cell cycle arrest to allow for DNA repair or to
programmed cell death. Genetic polymorphisms of mediators in this pathway may affect the
response to injury, repair and cell survival. In this study, we observed an association among
polymorphisms in the CHEK2 gene, a transducer in DNA damage signaling pathways, and
kidney function. We found some consistency in results among hypertensive enriched
samples of the FBPP, and in participants of the population-based ARIC study with
hypertension. Although the individual findings were restricted to white individuals, a meta-
analysis of effect estimates was consistent with a significant effect across the subpopulation.
In particular, we found that one tag-SNP, rs5762764, was associated with eGFR in white
individuals in HyperGEN and GENOA. The rs5762764 minor allele (G) showed a protective
effect of increased eGFR for each copy of the minor allele among white FBPP individuals
and among hypertensive individuals in the ARIC study. The findings in the FBPP were
robust to exclusion of diabetic individuals (Supplementary Data online), suggesting that the
genetic effects on kidney function may not be disease specific, but may affect the
downstream response to injury in different forms of kidney damage. Alternatively,
polymorphisms in CHEK2 may be important in influencing kidney function in hypertension-
related kidney injury.
The CHEK2 protein is ubiquitous. CHEK2 is an effector kinase that activates the tumor
suppressor protein p53, which leads to cell arrest and apoptosis. Because CHEK2 and other
kinases play a key role on cell survival, polymorphisms in the CHEK2 gene may contribute
to varying degree of apoptosis of intrinsic kidney cells in response to injury. For example, it
may affect the recovery of epithelial tubular cell damage in acute renal failure or it
contribute to reduced renal mass in chronic kidney injury. Recent studies suggest that
angiotensin II, whose infusion may cause systemic hypertension in animals, mediates
oxidative stress in the kidney53 and promotes apoptosis of intrinsic renal cells.54,55 The
role of this gene in angiotensin II–induced and hypertension-related kidney injury needs
further exploration in experimental models and in population studies.
Replication plays a key role in the assessment of the validity of genotype–phenotype
associations, because type 1 error is not expected to replicate more than by chance alone.
Our findings are particularly robust because the replication was achieved using the same
study design, phenotype (eGFR), genetic marker, and in a population of similar ancestry as
has been suggested by the National Cancer Institute and the National Human Genome
Research Institute Working Group on guidelines for replication in association studies.56
We also attempted to evaluate the generalizability of our study results to African-American
populations. The rs5762764 allele frequency was low in African Americans and haplotypes
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including the minor allele of this SNP were uncommon in these individuals. Therefore,
population-specific linkage disequilibrium and power may account for the lack of
association in African Americans. African-American individuals in HyperGEN were also 10
years younger than whites and although we adjusted for age, we may have not fully
accounted for the age-differences in the samples. In addition, because we relied on
estimating equations for measurement of kidney function, misclassification of the outcome
may have occurred.
In conclusion, we have shown that a polymorphism of the CHEK2 gene is associated with
measures of kidney function. These results suggest that CHEK2, a protein involved in cell
cycle regulatory pathways, may influence kidney function in the context of hypertension.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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